594488 Disclosed herein are pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent, wherein the hydrophilic binder is selected from a cellulose-based excipient selected from the group consisting of C3-C10 alkyl hydroxymethyl cellulose, aryl hydroxymethyl cellulose, and substituted aryl hydroxymethyl cellulose a naturally occurring carbohydrate polymer selected from starch and pregelatinized starch an anionic polymer selected from acrylic acid homopolymers cross-linked with allyl sucrose or allyl pentaerythritol a polymer of lactic acid or copolymer of lactic and glutamic acid a gelatin or a modified gelatin and chitosan. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.
